Lysosome pharmacology and toxicology. 1996

R Wattiaux, and S Wattiaux-De Coninck
Laboratoire de Chimie Physiologique, Facultés Universitaires Notre-Dame de la Paix, Namur, Belgium.

UI MeSH Term Description Entries
D008247 Lysosomes A class of morphologically heterogeneous cytoplasmic particles in animal and plant tissues characterized by their content of hydrolytic enzymes and the structure-linked latency of these enzymes. The intracellular functions of lysosomes depend on their lytic potential. The single unit membrane of the lysosome acts as a barrier between the enzymes enclosed in the lysosome and the external substrate. The activity of the enzymes contained in lysosomes is limited or nil unless the vesicle in which they are enclosed is ruptured or undergoes MEMBRANE FUSION. (From Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed). Autolysosome,Autolysosomes,Lysosome
D010599 Pharmacokinetics Dynamic and kinetic mechanisms of exogenous chemical DRUG LIBERATION; ABSORPTION; BIOLOGICAL TRANSPORT; TISSUE DISTRIBUTION; BIOTRANSFORMATION; elimination; and DRUG TOXICITY as a function of dosage, and rate of METABOLISM. LADMER, ADME and ADMET are abbreviations for liberation, absorption, distribution, metabolism, elimination, and toxicology. ADME,ADME-Tox,ADMET,Absorption, Distribution, Metabolism, Elimination, and Toxicology,Absorption, Distribution, Metabolism, and Elimination,Drug Kinetics,Kinetics, Drug,LADMER,Liberation, Absorption, Distribution, Metabolism, Elimination, and Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

R Wattiaux, and S Wattiaux-De Coninck
August 1952, A.M.A. archives of ophthalmology,
R Wattiaux, and S Wattiaux-De Coninck
August 1963, Archives of ophthalmology (Chicago, Ill. : 1960),
R Wattiaux, and S Wattiaux-De Coninck
August 1951, A.M.A. archives of ophthalmology,
R Wattiaux, and S Wattiaux-De Coninck
August 1954, A.M.A. archives of ophthalmology,
R Wattiaux, and S Wattiaux-De Coninck
August 1953, A.M.A. archives of ophthalmology,
R Wattiaux, and S Wattiaux-De Coninck
January 1978, The Medical annual,
R Wattiaux, and S Wattiaux-De Coninck
August 1955, A.M.A. archives of ophthalmology,
R Wattiaux, and S Wattiaux-De Coninck
January 1961, The Medical annals of the District of Columbia,
R Wattiaux, and S Wattiaux-De Coninck
May 1970, Science (New York, N.Y.),
R Wattiaux, and S Wattiaux-De Coninck
June 1975, Journal of steroid biochemistry,
Copied contents to your clipboard!